Harmony Biosciences Holdings, Inc.
HRMYHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeHarmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. Valued at $1.83B, HRMY is a small-cap name in its sector. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.
Market Cap
$1.83B
Beta
0.96
P/E (TTM)
12.74
P/E (Fwd)
5.66
EPS (TTM)
$2.48
EPS (Fwd)
$5.58
ROE
17.9%
ROA
10.2%
Cash
$640.9M
Total Debt
$164.6M
Free CF
$149.7M
52W Change
-11.2%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $640.9M in cash comfortably exceeding the $164.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow comes in at $149.7M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 17.9%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Return on assets of 10.2% further supports the picture of efficient asset utilization. Revenue has grown from $437.9M (2022) to $868.5M (2025), reflecting a 98% increase over the period.
With cash comfortably exceeding debt, HRMY has financial flexibility that may help navigate uncertain periods. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing HRMY.